Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial will study the role of a temporary tourniquet around the uterus to reduce blood loss in management of patients with abnormally implanted placenta who will undergo removal of the uterus.
Patients included in this study were subjected to:
A detailed second-level trans-abdominal and trans-vaginal ultrasound will be scheduled and conducted before the date of delivery, by a single operator in the department's Ultrasound Unit using a GE Voluson F8 ultrasound system (GE Healthcare, Zipf, Austria).
Trans-abdominal ultrasound will be done in a supine position with both a full and an empty bladder to document fetal biometry, estimated fetal weight, amniotic fluid index and to screen signs of placental invasion. These signs include on grayscale ultrasound, loss of clear zone, myometrial thinning, presence of placental lacunae, bladder wall interruption, placental bulge and focal exophytic mass; and on color Doppler imaging (CDI), uterovesical hypervascularity; subplacental hypervascularity; bridging vessels and placental lacunae feeder vessels. The placenta was recorded as 'low lying' when its edge was 0.5-2 cm from the internal os of the uterine cervix on trans-vaginal ultrasound. When the placenta was < 0.5 cm from the internal os or completely covering it, it was defined as placenta previa (marginal or complete)
The estimated total blood loss will be derived by multiplying the calculated pregnancy blood volume by percentage of blood volume lost.
Pregnancy blood volume = (0.75 × {[maternal height (inches) × 50] + [maternal weight in pounds × 25]}) Percent of blood volume lost = ({predelivery Hematocrit - postdelivery hematocrit}/pre-delivery hematocrit)
Total blood loss = pregnancy blood volume × percent of blood volume lost - The need for blood transfusion and its amount intra or post-operative will be recorded
- For patients who had intra or postoperative blood transfusion, the actual blood loss was calculated through Lopez-Picado's formula: Estimated blood loss (m) = [Estimated blood volume x (pre-operative hematocrit-post-operative hematocrit) + vol. of transfused packed red blood cells]/average hematocrit Where Average hematocrit is the sum of preoperative & postoperative hematocrit levels, divided by 2.
According to the International Council for Standardization in Hematology (ICSH):
For women: Estimated blood volume (EBV) (ml) = Plasma vol. (ml) + Red cell vol. (ml) = [weight (kg) ^0.425 × height (cm) ^0.725 x 0.007184 x2.217] + [age(years) x1.061]
Pre and 24-h post-operative hemoglobin (g/dl).
Operative time and post-operative hospital stay will be recorded.
Close post-operative monitoring of the patients' vital signs, drain output and urine output
Presence or absence of intraoperative complications; bladder, ureteric, bowel or vascular injuries will be recorded.
Monitoring for post-operative morbidities as postpartum hemorrhage, DVT, claudications, or the need for ICU admission, all will be recorded.
Randomization: The 30 included participants will be subjected to block randomization into 5 blocks containing 6 participants each by a single member of the research team.
Block 1 TNNTTN Block 2 TTNNNT Block 3 NTNNTT Block 4 NNTNTT Block 5 TNTNTN
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tourniquet Group | Experimental | A temporary sub-placental uterine tourniquet will be temporarily applied before fetal extraction. |
|
| Non-Tourniquet Group | Experimental | No tourniquet will be used in this arm. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last) | Procedure | Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy. |
| Measure | Description | Time Frame |
|---|---|---|
| The estimated total blood loss. | ml | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Operative time | minutes | From the start of the procedure till the end. |
| Need for blood transfusion | Number of units of packed blood transfused |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed Eltawil, MSc | Contact | +201100009781 | ahmed.eltawil512@gmail.com | |
| Abdalla Mousa, MD | Contact | +201277664430 | dr_abdallamousa@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Moutaz M Elsherbini, MD | Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Ethics Committee, Faculty of Medicine, Cairo University | Recruiting | Cairo | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34670307 | Background | Alves ALL, Silva LBD, Costa FDS, Rezende GC. Management of placenta accreta spectrum. Rev Bras Ginecol Obstet. 2021 Sep;43(9):713-723. doi: 10.1055/s-0041-1736371. Epub 2021 Oct 20. No abstract available. | |
| 35369280 | Background | Altal OF, Qudsieh S, Ben-Sadon A, Hatamleh A, Bataineh A, Halalsheh O, Amarin Z. Cervical tourniquet during cesarean section to reduce bleeding in morbidly adherent placenta: a pilot study. Future Sci OA. 2022 Mar 8;8(4):FSO789. doi: 10.2144/fsoa-2021-0087. eCollection 2022 Apr. |
Not provided
Not provided
All the individual participant data related to the published results after deidentification (texts, tables, figures and appendices)
starting 6 months after publication and no end date
anyone who wishes to access the data
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder | Procedure | Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy. |
|
| before, during and immediately after the procedure |
| Internal organ injury (Bladder, intestine, ureter) | Injury to bladder, intestine or ureter | during the operative procedure |
| Inadvertent injury to the pelvic vessels (eg. Injury to the ovarian vessels while inserting the tourniquet) | Injury to major pelvic vessel | during the operative procedure |
| ICU admission | post operative ICU admission | immediately after the procedure |
| Neonatal APGAR score | APGAR (Appearance, Pulse, Grimace, Activity and Respiration) score of the newborn. The score is scaled from 0 to 10, where a higher score indicates a better outcome | at 1 and 5 minutes after birth |
| 30057649 | Background | Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers. Dis Markers. 2018 Jul 3;2018:1507674. doi: 10.1155/2018/1507674. eCollection 2018. |
| 34725137 | Background | Donovan BM, Shainker SA. Placenta Accreta Spectrum. Neoreviews. 2021 Nov;22(11):e722-e733. doi: 10.1542/neo.22-11-e722. |
| 34733857 | Background | Huang J, Zhang X, Liu L, Duan S, Pei C, Zhao Y, Liu R, Wang W, Jian Y, Liu Y, Liu H, Wu X, Zhang W. Placenta Accreta Spectrum Outcomes Using Tourniquet and Forceps for Vascular Control. Front Med (Lausanne). 2021 Oct 18;8:557678. doi: 10.3389/fmed.2021.557678. eCollection 2021. |
| 34225385 | Background | Hussein AM, Elbarmelgy RA, Elbarmelgy RM, Thabet MM, Jauniaux E. Prospective evaluation of impact of post-Cesarean section uterine scarring in perinatal diagnosis of placenta accreta spectrum disorder. Ultrasound Obstet Gynecol. 2022 Apr;59(4):474-482. doi: 10.1002/uog.23732. Epub 2022 Mar 8. |
| 34461077 | Background | Jauniaux E, Hussein AM, Elbarmelgy RM, Elbarmelgy RA, Burton GJ. Failure of placental detachment in accreta placentation is associated with excessive fibrinoid deposition at the utero-placental interface. Am J Obstet Gynecol. 2022 Feb;226(2):243.e1-243.e10. doi: 10.1016/j.ajog.2021.08.026. Epub 2021 Aug 28. |
| 33204176 | Background | Morlando M, Collins S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. Int J Womens Health. 2020 Nov 10;12:1033-1045. doi: 10.2147/IJWH.S224191. eCollection 2020. |
| 18639209 | Background | Stafford I, Dildy GA, Clark SL, Belfort MA. Visually estimated and calculated blood loss in vaginal and cesarean delivery. Am J Obstet Gynecol. 2008 Nov;199(5):519.e1-7. doi: 10.1016/j.ajog.2008.04.049. Epub 2008 Jul 17. |
| ID | Term |
|---|---|
| D010921 | Placenta Accreta |
| D006470 | Hemorrhage |
| ID | Term |
|---|---|
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D010922 | Placenta Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided